跳至主要内容
临床试验/NCT05163054
NCT05163054
尚未招募
不适用

Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China

Peking University Third Hospital1 个研究点 分布在 1 个国家目标入组 500 人2022年6月

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Type 1 Diabetes
发起方
Peking University Third Hospital
入组人数
500
试验地点
1
主要终点
HbA1c
状态
尚未招募
最后更新
3年前

概览

简要总结

For last decade, the innovation of mobile health platform has brought new opportunities for disease management. Previous studies have shown that health management programs based on mobile platforms for patients with diabetes can improve patients' glucose control, self-management ability and quality of life. Type 1 diabetes mellitus (T1DM) due to its characteristics needs long-term linkage care throughout the lifespan cycle of patients. Therefore, this study intends to construct a prospective and open T1DM cohort based on mobile application and platform, to deliver home-community-hospital joint management for patients, and to provide follow-up online or offline every 3 months lasting for 10 years. Mainly, the objective of this study is to observe the blood glucose control outcome of T1DM patients. Secondly, the control of comprehensive metabolic indicators such as blood pressure and blood lipid, occurrence and progression of acute and chronic complications, and psychosocial status were included as well, expecting to provide scientific evidence for continuously improving the quality of T1DM management.

注册库
clinicaltrials.gov
开始日期
2022年6月
结束日期
2032年1月
最后更新
3年前
研究类型
Observational
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • At least 12 years old;
  • Diagnosed as type 1 diabetes according to World Health Organization (WHO) criteria in 1999;
  • Be able to use smart mobile phones;
  • Informed consent and voluntary participation.

排除标准

  • Secondary diabetes;
  • Complicated with malignant diseases, such as cancer, hepatic and renal failure;
  • Complicated with cognitive impairment or mental illness;
  • Be pregnant or lactating at the time of enrollment.

结局指标

主要结局

HbA1c

时间窗: Outcome evaluation at 10 years.

HbA1c is one of the indicators that reflects the level of blood glucose control overall. Blood sample will be required and tested.

Time in range (TIR)

时间窗: Outcome evaluation at 10 years.

TIR is one of the indicators that reflects the level of blood glucose control from the point of view of target time. Continuous glucose monitoring (CGM) devices will be used.

Incidence of hypoglycemia

时间窗: Outcome evaluation at 10 years.

Incidence of hypoglycemia is one of the indicators that reflects the level of blood glucose control. Hypoglycemia is defined as blood glucose lower than 3.9mmol/L with or without symptoms. Incidence of hypoglycemia is occurence times per month according to patients self-reported.

次要结局

  • Anxiety condition.(Outcome evaluation at 10 years.)
  • Comprehensive metabolic control(Outcome evaluation at 10 years.)
  • Occurrence of Diabetes-related complications.(Outcome evaluation at 10 years.)
  • Progression of Diabetes-related complications.(Outcome evaluation at 10 years.)
  • Depression condition.(Outcome evaluation at 10 years.)
  • Life quality.(Outcome evaluation at 10 years.)

研究点 (1)

Loading locations...

相似试验